Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543936 | 1.00 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL25370300 | 0.92 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL30543961 | 0.92 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL30543892 | 0.86 | KDR (0.55) | KMT2AMEN1 | |
| SCHEMBL25367369 | 0.86 | KDR (0.55) | KMT2AMEN1 | |
| SCHEMBL25369081 | 0.85 | DHX9 (0.48) | RAB9A | |
| SCHEMBL30543897 | 0.85 | DHX9 (0.48) | RAB9A | |
| SCHEMBL25368567 | 0.83 | EPHX2 (0.54) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL30543894 | 0.83 | EPHX2 (0.54) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL25368564 | 0.81 | KDM4E (0.48) | NPC1RAB9ASMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | NPC1 2484/4885RAB9A 388/4885SMN1; SMN2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.